The authors examine the use of pembroluzimab, a monoclonal antibody designed to block the PD-1 pathway in metastatic melanoma. PD-1 ligand has been found to be expressed on several cancer cells, including metastatic melanoma, and when bound to the PD-1 cell-surface receptor on T-cells, functions to reduce immune mediated destruction of those cancerous cells. Thus, […]